Peter Attia would rather keep you on 2.5 mg of Mounjaro than let you yo-yo on 15.

Peter Attia, MD, says slow and steady beats maximum weight loss, and that going on and off these drugs is probably the worst thing you can do.

GLP-1s: Safe Dosing, Nutrition & Impact on Longevity | Rhonda Patrick, Ph.D.

Five years ago, Peter Attia watched muscle fall off his patients on semaglutide and thought maybe these drugs weren't worth it. Today, about 15 to 20% of his patients are on tirzepatide, and he says virtually anybody can use them safely, including for long-term muscle health.

The difference is not the drug. It is everything his practice now does around the drug.

He shared his current approach in a recent conversation with Rhonda Patrick, and the numbers matter. Most of his patients never go above the starting doses. Some stay at 2.5 mg of tirzepatide indefinitely. And none of them are losing the kind of muscle mass he used to see on DEXA scans.

Yo-yoing on and off is probably a bad idea

Attia's strategy is built on one rule: slow and steady wins the race. He has seen anecdotal data, and heard from other clinicians, that cycling on and off GLP-1s is likely harmful.

So he tells every patient the same thing. He would rather they stay on 2.5 mg until a better drug comes along than go to 10 mg, lose a ton of weight, come off, gain it back, go back on and lose it again.

"The idea of being on a saw is probably a bad idea," he says.

I'd probably rather you were on 2.5 milligrams until there was a new drug that we felt was even better than you're on 10 milligrams, you lose a ton of weight, you come off, you gain, you go back on.Peter Attia MD

Why this matters if you haven’t started yet: If you are starting tirzepatide, this approach flips the typical telehealth model, which often pushes dose escalation every four weeks. Attia's patients may never titrate up at all.

Most of the benefit comes at the lowest doses

Tirzepatide starts at 2.5 mg, and some patients get enough benefit there to stop. The data, Attia says, suggests you are getting most of the value by about 10 mg.

Once you go to 12.5 or 15 mg, the two highest doses, you still get a benefit. But like most drugs, you are getting the majority of the effect at the lowest dose.

He estimates that 5 to 7.5 mg of tirzepatide is where most patients see the bulk of their results. And again, he would much rather someone be slow and steady at that level than push for maximum and rapid weight loss.

The new problem is protein, not the drug

When patients are on tirzepatide, Attia says you do not really want a steak. You do not want a big chicken breast. You might not even want an omelette.

But you still need to hit 1.6 grams of protein per kilogram of ideal body weight. That is the target his practice uses to protect muscle mass.

So many of his patients are doing a bunch of liquid shakes. He acknowledges the irony: you can sit there and criticize processed food all you want, but if the alternative is not getting enough protein on a drug that makes you anorexic, the answer is clear.

You might be doing a bunch of liquid shakes. We can sit here and poo poo processed food and say, how disgusting is it that people have to resort to eating shakes. But if the alternative is they're not getting enough protein and they're on a drug that is making them anorexic, the answer's clear.Peter Attia MD

Why this matters if you haven’t started yet: This is the group of people who need easy-to-digest protein sources the most. If solid food is not happening, a shake is not a failure. It is the strategy.

DEXA scans before and after, and the muscle is staying

Attia's practice runs DEXA scans before patients start and after they have been on the drug. They are not seeing the type of muscle loss they saw with what he calls their version 1 approach five years ago.

The difference is deliberate attention. Protein targets. Training. Slow titration. And in some cases, micro-dosing the drug so patients never lose weight at all.

He uses 2.5 mg in patients who have diabetes but low body weight

Attia has two patients in his practice with diabetes who already have a BMI of 23. It seemed counterintuitive to give tirzepatide to people who did not need to lose weight.

But after detailed consultation with Ralph DeFronzo, a diabetes researcher and previous podcast guest, Attia decided a GLP-1 agonist was going to be part of the regimen.

They have been able to keep these patients on 2.5 mg without any weight loss, using very careful strategies around nutrition. And the effect on their diabetes has been profound.

In one case, the patient had an oral glucose tolerance test that was unrecognizable. Severe metabolic dysfunction in someone who looked completely normal. Even genetic testing could not explain where the beta cell fatigue was coming from.

Within three months on 2.5 mg of tirzepatide, that patient's OGTT had almost normalized. Attia suspects it will fully normalize by six months.

Why this matters if you haven’t started yet: This is the interesting question for longevity, Attia says: can you use a micro-dose of a GLP-1 to improve metabolic health and Alzheimer's biomarkers without losing weight or lean mass?

The injection site might matter more than you think

Patients have told Attia that when they inject tirzepatide in the abdomen, the appetite-suppressing effects are greater than if they inject in the leg or butt.

He looked into it and found some mechanistic data suggesting you might be getting more vagal tone, the nerve signal that affects satiety, when you inject in the abdomen.

He does not know if it is correct. It would need to be studied. But if there is a way to inject the drug that minimizes the anorexic effect, that could be a feature for some people and a bug for others.

You have to understand how to use the tool.

Notice what has changed in five years. Not the molecule. Not the pen. The dose, the protein target, the injection site, the decision to stay low instead of climbing high and fast.

Attia says virtually anybody can use these drugs safely now, but it requires a ton of deliberate attention. If you are on one and not tracking protein or muscle mass, you are running the version 1 playbook. That is the one where muscle fell off and he was not sure the drugs were worth it.

Questions people ask

What is the lowest effective dose of Mounjaro or Zepbound?

Some patients get enough benefit at the starting dose of 2.5 mg tirzepatide and never need to go higher. Dr. Attia says most of the benefit comes by 10 mg, and he prefers patients stay at lower doses long-term rather than push to the maximum.

Can you stay on a low dose of a GLP-1 forever?

Dr. Attia says he would rather a patient stay on 2.5 mg of tirzepatide indefinitely than cycle on and off higher doses. He believes yo-yoing is probably a bad idea based on anecdotal data he and other clinicians have seen.

Does it matter where you inject Mounjaro or Zepbound?

Some patients report stronger appetite suppression when injecting tirzepatide in the abdomen versus the leg or butt. Dr. Attia found some data suggesting abdominal injections may increase vagal tone, but this has not been formally studied.

PA
Peter Attia MD

Peter Attia is a physician focused on longevity and metabolic health. He prescribes tirzepatide (Mounjaro, Zepbound) to about 15 to 20% of his patients. 297,728 views on the original video.

Watch the original on YouTube →

Trending Topics

Free, from GLP‑1 Classified

Thinking about a GLP‑1? Read our guide before you start.

The questions to ask, the costs nobody mentions, and what the first month really feels like. Plus a short weekly letter for people on, or considering, a GLP‑1. We are not a pharmacy or a telehealth brand. We work for you, not for them.

No spam. Unsubscribe any time.